These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28142309)

  • 21. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.
    Levi Z; Birkenfeld S; Vilkin A; Bar-Chana M; Lifshitz I; Chared M; Maoz E; Niv Y
    Int J Cancer; 2011 May; 128(10):2415-24. PubMed ID: 20658527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer.
    Castiglione G; Zappa M; Grazzini G; Mazzotta A; Biagini M; Salvadori P; Ciatto S
    Br J Cancer; 1996 Jul; 74(1):141-4. PubMed ID: 8679448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
    Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
    Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
    Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.
    Giorgi Rossi P; Carretta E; Mangone L; Baracco S; Serraino D; Zorzi M;
    J Med Screen; 2018 Mar; 25(1):32-39. PubMed ID: 28195508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.
    Manfredi S; Philip J; Campillo B; Piette C; Durand G; Riou F; Bretagne JF
    Eur J Cancer Prev; 2011 Jul; 20(4):277-82. PubMed ID: 21633201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interval cancers and episode sensitivity in population-based screening programmes for colorectal cancer: a systematic review].
    Domènech X; Garcia M; Benito L; Binefa G; Vidal C; Milà N; Moreno V
    Gac Sanit; 2015; 29(6):464-71. PubMed ID: 26341155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
    Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms.
    Dancourt V; Lejeune C; Lepage C; Gailliard MC; Meny B; Faivre J
    Eur J Cancer; 2008 Oct; 44(15):2254-8. PubMed ID: 18760592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study.
    Denis B; Gendre I; Perrin P
    J Med Screen; 2015 Jun; 22(2):76-82. PubMed ID: 25576338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.
    Zorzi M; Hassan C; Senore C; Capodaglio G; Turrin A; Narne E; Mussato A; Rizzato S; Chinellato E; Zamberlan S; Repici A; Rugge M
    J Med Screen; 2021 Jun; 28(2):131-139. PubMed ID: 32393153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
    George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
    Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity of a colorectal cancer screening program based on a guaiac test: a population-based study.
    Giai J; Exbrayat C; Boussat B; Poncet F; Bureau du Colombier P; Colonna M; Seigneurin A
    Clin Res Hepatol Gastroenterol; 2014 Feb; 38(1):106-11. PubMed ID: 23896367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
    Church TR; Ederer F; Mandel JS
    J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.